Biological therapy for chronic obstructive pulmonary disease (COPD): Effectiveness and safety
- 12 April 2026
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 256, 108815
Abstract
No abstract availableKeywords
Funding Information
- Horizon 2020 (MSCA-IF-EF-ST #894990)
- European Regional Development Fund
- European Commission
- Instituto de Salud Carlos III (PI21/01564)
This publication has 18 references indexed in Scilit:
- Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 InflammationNew England Journal of Medicine, 2024
- Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsNew England Journal of Medicine, 2023
- Methods for developing and reporting living evidence synthesisJournal of Clinical Epidemiology, 2022
- A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophilsHeliyon, 2022
- Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trialThe Lancet Respiratory Medicine, 2022
- Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trialThe Lancet Respiratory Medicine, 2021
- Benralizumab for the Prevention of COPD ExacerbationsNew England Journal of Medicine, 2019
- Long term survival after admission for COPD exacerbation: A comparison with the general populationRespiratory Medicine, 2018
- Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2017
- Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a studyThe Lancet Respiratory Medicine, 2014